Morgan Stanley assumed coverage of Ultragenyx (RARE) with an Overweight rating and $64 price target The firm sees continued strong Crysvita growth, with Latin America representing the largest growth opportunity, while the pipeline continues to advance, representing further potential upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline
- Optimistic Outlook for Ultragenyx Pharmaceutical Amid Promising Gene Therapy Developments
- Ultragenyx’s BLA for UX111 accepted by FDA for priority review
- Ultragenyx price target raised to $136 from $121 at Canaccord
- 3 Best Stocks to Buy Now, 2/18/2025, According to Top Analysts